🇺🇸 FDA
Patent

US 9526796

Peptide-based in vivo siRNA delivery system

granted A61KA61K47/549A61K47/64

Quick answer

US patent 9526796 (Peptide-based in vivo siRNA delivery system) held by Arrowhead Pharmaceuticals, Inc. expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K47/549, A61K47/64, A61K47/6415, A61P